Australia markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8000+0.2100 (+8.11%)
At close: 04:00PM EDT
2.8600 +0.06 (+2.14%)
Pre-market: 09:13AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5900
Open2.6800
Bid2.7700 x 1300
Ask2.8000 x 1000
Day's range2.6400 - 2.8950
52-week range1.1400 - 3.3300
Volume2,009,541
Avg. volume2,035,693
Market cap274.584M
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

    -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months -- -- Gritstone incorporating GMP-grade raw materials in the manufacture of its samRNA v

  • GlobeNewswire

    Gritstone bio Announces Workforce Reduction

    EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study. “The lack

  • GlobeNewswire

    Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

    EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: 2024 BIO CEO & Investor Conference (Panel)Panel Title: Reviewing Vaccine Pipeline Breakthroughs and BarriersDate and Time: Monday, February 26, 2024 at 2:00pm ETLocation: New York, NY IO360 Summit (Panel)Panel